Free Trial
NASDAQ:EDSA

Edesa Biotech Q2 2026 Earnings Results & Report

Edesa Biotech logo
$2.86 -0.08 (-2.55%)
As of 03:47 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Edesa Biotech missed analyst earnings expectations in its Q2 2026 results, released May 14, 2026. The company reported EPS of -$0.49 versus the -$0.24 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2026
Report Date
Time
Before Market Opens

Edesa Biotech EPS Results

Actual EPS
-$0.49
Consensus EPS
-$0.24
Beat/Miss
Missed by -$0.25
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 8 quarters

Edesa Biotech Revenue Results

Actual Revenue
N/A
Expected Revenue
$0.05 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Upcoming Earnings

Edesa Biotech's next earnings date is estimated for Friday, December 11, 2026, based on past reporting schedules.

Conference Call Resources

Edesa Biotech Q2 2026 Earnings FAQ

Edesa Biotech (NASDAQ:EDSA) reported earnings of -$0.49 per share for Q2 2026, missing the consensus estimate of -$0.24. The report was announced on Thursday, May 14, 2026.

Edesa Biotech's next earnings date is estimated for Friday, December 11, 2026. MarketBeat tracks confirmed and estimated earnings dates for Edesa Biotech on the company's earnings history page.

Edesa Biotech Earnings Headlines

Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.tc pixel
Edesa Biotech prices $25M equity offering
See More Edesa Biotech Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Edesa Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Edesa Biotech and other key companies, straight to your email.

About Edesa Biotech

Edesa Biotech (NASDAQ:EDSA) is a clinical-stage biopharmaceutical company focused on developing therapeutics for inflammatory and immune-mediated diseases. The company does not have any marketed products and concentrates on advancing investigational treatments through clinical development and regulatory evaluation.

Edesa’s lead program has been EB01, a topical therapy being developed for chronic hand eczema, a painful inflammatory skin condition that can significantly affect patients’ daily activities. The company has also evaluated EB05, an antibody-based treatment candidate intended to address excessive inflammation associated with acute respiratory distress syndrome and other serious conditions. The status of individual programs may change as clinical and regulatory work progresses.

Edesa is headquartered in Markham, Ontario, Canada, and has conducted development activities in Canada and the United States. The company was founded to pursue therapies for diseases with limited treatment options and has worked with research, clinical, and regulatory partners in advancing its programs. Par Nijhawan has served as the company’s chief executive officer.

View Edesa Biotech Profile